Immunogenicity of a recombinant hemagglutinin neuraminidase-<i>Porcine rubulavirus</i> produced by <i>Escherichia coli</i> of <i>Porcine rubulavirus</i> gives protective immunity of litter after challenge

Abstract

Porcine rubulavirus (PRV) is a contagious virus that affects the Mexican swine industry. This work aimed to evaluate the immunogenicity of an rHN-PorPV candidate vaccine on pregnant sows, and the protective efficacy afforded to their 7-day-old suckling piglets against PRV lethal challenge. Three sows were immunized with rHN-PorPV formulated with immunestimulating complex (ISCOMs) and two sows with rHN-PorPV protein alone as well as a mock-immunized pregnant sow (negative control). Quantitative ELISA detected a high concentration of anti-rHN-PorPV Immunoglobulin G (IgG) antibodies in sow sera after the second dose of vaccine administered on day 14 until farrowing, showing viral-neutralizing and cross-neutralization activity against different variants of PRV. Sera samples from piglets of immunized sows (with or without adjuvant), showed high concentrations of IgG antibodies.As expected, piglets from the negative control sow (n=5), exhibited severe signs of disease and 100% of mortality after PRV challenge study. Conversely, 75% and 87.5% of the piglets born from the rHN-PorPV and the rHN-PorPV-ISCOMs-immunized sows (n=8), survived, respectively, showing milder PRV clinical signs. Our data indicate that rHN-PorPV candidate vaccine produced in E. coli induces efficient humoral response in pregnant sows and that the maternally derived immunity provides high protection to suckling piglets against PRV lethal challenge.

A Candidate Antigen of the Recombinant Membrane Protein Derived from the Porcine Deltacoronavirus Synthetic Gene to Detect Seropositive Pigs

“…The antibody response was dramatically higher using a Matrix-M TM as an adjuvant. Matrix-M TM selection was according to our research group [ 55 , 72 , 73 ]; we have observed that this immunostimulatory complex is an adjuvant that enhances strong immunogenicity using advanced technology in a nanocarrier to deliver antigens [ 59 ]. These results are in agreement with previously reported studies, which described antigen enhanced with Matrix-M TM as being highly immunogenic and inducing both antibody and cellular immune responses [ 57 ].…”